1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Laboratory and OCT findings of symptomatic and asymptomatic lesions
Symptomatic (n = 17) Asymptomatic (n = 17) P Value
Male, No. (%) 14 (82.4) 15 (88.2) >.99
Age (yr) 72 ± 10 68 ± 10 .19
Degree of stenosis (%) 84 ± 12 79 ± 7 .26
Laboratory parameters 
    Total cholesterol (mg/dL) 183 ± 35 184 ± 30 .89
    Triglycerides (mg/dL) 153 ± 54 135 ± 42 .31
    HDL cholesterol (mg/dL) 45 ± 12 46 ± 11 .84
    LDL cholesterol (mg/dL) 107 ± 35 111 ± 30 .78
    C-reactive protein (mg/dL) 0.25 ± 0.23 0.24 ± 0.26 .93
    Hemoglobin A1C (mg/dL) 6.1 ± 1.0 6.4 ± 1.2 .59
Medications 
    Aspirin, No. (%) 16 (94.1) 14 (82.4) .6 
    Ticlopidine, No. (%) 0 (0) 1 (5.9) >.99
    Clopidogrel, No. (%) 15 (88.2) 12 (70.6) .39
    Cilostazol, No. (%) 3 (17.6) 6 (35.3) .44
    Statins, No. (%) 10 (58.8) 12 (70.6) .72
    Calcium channel blockers, No. (%) 4 (23.5) 6 (35.3) .71
    ARBs, No. (%) 8 (47.1) 7 (41.2) >.99
OCT findings 
    Thrombus 13 (76.5) 2 (11.8) <.001
    Neovascularization 10 (58.8) 3 (17.6) .03
    Ulceration 3 (17.6) 0 (0) .23
    Calcification 7 (41.2) 6 (35.3) >.99
    Lipid-rich component 16 (94.1) 12 (70.6) .17
    Plaque protrusion 4 (23.5) 2 (11.8) .66

Note:—ARBs indicates angiotensin II receptor blockers.